1. Signaling Pathways
  2. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  3. EGFR
  4. EGFR Inhibitors

EGFR Inhibitors

EGFR/ErbB1/HER1

ErbB2/HER2

ErbB3/HER3

ErbB4/HER4

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

EGFR Inducers, Inhibitors, Agonists, Antagonists & Activators
Product Name EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4 Purity
Osimertinib
EGFRL858R, IC50: 12 nM (Enzyme assays)
EGFRL858R/T790M, IC50: 1 nM (Enzyme assays)
      99.92%
Trastuzumab  
HER2
    99.80%
Gefitinib
EGFR
      99.94%
Erlotinib
EGFR, IC50: 2 nM (Cell Free Assay)
      99.54%
Cetuximab
Soluble EGFR, Kd: 0.201 nM
EGFR, Kd: 0.147 nM (Fixed A431 cells)
      99.60%
JBJ-09-063 TFA
EGFR L858R, IC50: 0.147 nM
EGFR L858R/T790M, IC50: 0.063 nM
EGFR L858R/T790M/C797S, IC50: 0.083 nM
EGFRLT/L747S, IC50: 0.396 nM
     
Afatinib
EGFR, IC50: 0.5 nM
EGFRL858R, IC50: 0.4 nM
EGFRL858R/T790M, IC50: 10 nM
HER2, IC50: 14 nM
    99.93%
AG490
EGFR
      99.92%
Lapatinib
EGFR, IC50: 10.2 nM (Cell Free Assay)
ErbB2, IC50: 9.8 nM (Cell Free Assay)
    99.83%
Neratinib
EGFR, IC50: 92 nM
HER2, IC50: 59 nM
    99.59%
Genistein
EGFR, IC50: 0.6 μM (Cell Assay)
      99.84%
Tucatinib  
HER2
    99.82%
AG-1478
EGFR, IC50: 3 nM
      99.22%
Mobocertinib
EGFR (WT)
EGFR exon 20 insertion
HER2
    99.60%
Pertuzumab  
HER2
    99.10%
Dacomitinib
EGFR, IC50: 6 nM
ErbB2, IC50: 45.7 nM
 
ErbB4, IC50: 73.7 nM
99.74%
Osimertinib mesylate
EGFRL858R/T790M, IC50: 1 nM
EGFRL858R, IC50: 12 nM
      99.94%
Erlotinib Hydrochloride
EGFR, IC50: 2 nM
      99.93%
Sapitinib
EGFR, IC50: 4 nM
ErbB2, IC50: 3 nM
HER3, IC50: 4 nM
  99.93%
Pyrotinib
EGFR, IC50: 13 nM
HER2, IC50: 38 nM
    99.61%
Gefitinib-based PROTAC 3
EGFR, DC50: 11.7 nM (HCC827(exon 19 del) cells)
EGFR, DC50: 22.3 nM (H3255 (L858R mutantion) cells)
      99.98%
Mubritinib  
HER2, IC50: 6 nM
    99.91%
NSC 228155
EGFR
      ≥98.0%
Tuxobertinib
EGFR, Kd: 0.2 nM
HER2, Kd: 0.76 nM
    99.94%
Gefitinib hydrochloride
EGFR
      99.85%
Pelitinib
EGFR, IC50: 38.5 nM
      98.80%
CUDC-101
EGFR, IC50: 2.4 nM
HER2, IC50: 15.7 nM
    99.19%
BI-4020
EGFRdel19 T790M C797S, IC50: 0.2 nM
EGFRdel19, IC50: 1 nM
EGFRWT, IC50: 190 nM
      ≥99.0%
Afatinib dimaleate
EGFR, IC50: 0.5 nM
EGFRL858R, IC50: 0.4 nM
EGFRL858R/T790M, IC50: 10 nM
HER2, IC50: 14 nM
    99.88%
TAS6417
EGFR, IC50: 1.1-8.0 nM
      99.81%
Canertinib
EGFR, IC50: 7.4 nM
ErbB2, IC50: 9 nM
    99.95%
Lazertinib
EGFRT790M
      99.73%
Rociletinib
EGFRL858R/T790M, Ki: 21.5 nM
EGFRT790M, Ki: 303.3 nM
      99.79%
Lapatinib ditosylate
EGFR, IC50: 10.8 nM (Cell Free Assay)
ErbB2, IC50: 9.2 nM (Cell Free Assay)
    99.95%
Varlitinib
HER1, IC50: 7 nM
HER2, IC50: 2 nM
 
HER4, IC50: 4 nM
≥98.0%
Lifirafenib
EGFR, IC50: 29 nM
EGFRL858R/T790M, IC50: 495 nM
      98.73%
Almonertinib
EGFRT790M, IC50: 0.37 nM
EGFRL858R/T790M, IC50: 0.29 nM
EGFRdel19 T790M, IC50: 0.21 nM
      99.98%
Butein
EGFR, IC50: 16 μM (in HepG2 cells)
      99.95%
Zorifertinib
EGFR, IC50: 0.3 nM
EGFRL858R, IC50: 0.2 nM
EGFRExon 19 deletion, IC50: 0.2 nM
      99.76%
Disitamab vedotin  
HER2
   
Alflutinib mesylate
EGFR
      99.96%
TAK-285
EGFR, IC50: 23 nM
HER2, IC50: 17 nM
    98.04%
Olmutinib
EGFRExon 19 deletion, IC50: 9.2 nM (Cell Assay)
EGFRL858R/T790M, IC50: 10 nM (Cell Assay)
      99.88%
EAI045
EGFR, IC50: 1.9 μM
EGFRL858R, IC50: 0.019 μM
EGFRT790M, IC50: 0.19 μM
EGFRL858R/T790M, IC50: 0.002 μM
      98.90%
AZ-5104
EGFRL858R/T790M, IC50: 1 nM
EGFRL858R, IC50: 1 nM
EGFRL861Q, IC50: 6 nM
EGFR, IC50: 25 nM
   
ErbB4, IC50: 7 nM
99.70%
Icotinib
EGFR, IC50: 5 nM
      99.95%
TX1-85-1    
ErbB3, IC50: 23 nM
  98.07%
Sunvozertinib
EGFR exon 20 insertion, IC50: 20.4 nM
EGFRL858R/T790M, IC50: 1.1 nM
Her2 Exon20 YVMA, IC50: 7.5 nM
    99.92%
PD168393
EGFR, IC50: 0.7 nM
      98.60%
Chrysophanol
EGFR
      99.20%
BMS-690514
EGFR, IC50: 5 nM
HER2, IC50: 20 nM
 
HER4, IC50: 60 nM
99.07%
EGFR-IN-7
EGFR (WT), IC50: 7.92 nM
EGFR (C797S/T790M/L858R), IC50: 0.218 nM
      99.76%
Tyrphostin 23
EGFR, IC50: 35 μM (Cell Assay)
EGFR, Ki: 11 μM
      99.43%
Pyrotinib dimaleate
EGFR, IC50: 13 nM
HER2, IC50: 38 nM
    99.63%
Canertinib dihydrochloride
EGFR, IC50: 7.4 nM
ErbB2, IC50: 9 nM
    99.12%
PD153035
EGFR, Ki: 6 pM
EGFR, IC50: 25 pM
      99.24%
Tesevatinib
EGFR, IC50: 0.3 nM
ErbB2, IC50: 16 nM
    99.21%
PD158780
EGFR, IC50: 8 μM (Cell Assay)
ErbB2, IC50: 49 nM (Cell Assay)
ErbB3, IC50: 52 nM (Cell Assay)
ErbB4, IC50: 52 nM (Cell Assay)
99.52%
Icotinib Hydrochloride
EGFR, IC50: 5 nM
      99.84%
AEE788
EGFR, IC50: 2 nM
ErbB2, IC50: 6 nM
    98.39%
Nazartinib
EGFRL858R/T790M, Ki: 31 nM
      99.48%
CP-724714  
ErbB2, IC50: 10 nM
    98.53%
Osimertinib dimesylate
EGFRL858R, IC50: 12 nM
EGFRL858R/T790M, IC50: 1 nM
      99.96%
TAS0728
EGFR, IC50: 65 nM
HER2, IC50: 13 nM
 
HER4, IC50: 8.5 nM
99.15%
WZ4002
EGFRL858R, IC50: 2 nM (Cell Assay)
EGFRL858R/T790M, IC50: 8 nM (Cell Assay)
EGFRE746_A750, IC50: 3 nM (Cell Assay)
EGFRE746_A750/T790M, IC50: 2 nM (Cell Assay)
      99.76%
Avitinib maleate
EGFR, IC50: 7.68 nM
      ≥98.0%
Mobocertinib succinate
EGFR exon 20 insertion
EGFR (WT)
HER2
    99.61%
(Rac)-JBJ-04-125-02
EGFR (L858R/T790M), IC50: 0.26 nM
      98.01%
Daphnetin
EGFR, IC50: 7.67 μM
      99.21%
WHI-P154
EGFR, IC50: 4 nM
      99.39%
Tarloxotinib bromide  
EGFR/HER2
    99.26%
Allitinib tosylate
EGFR, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 12 nM
ErbB2, IC50: 3 nM
 
ErbB4, IC50: 0.8 nM
99.83%
WHI-P180
EGFR, IC50: 4 μM
      99.62%
Falnidamol
EGFR, IC50: 3 nM
ErbB2, IC50: 3.4 μM
    99.05%
Tarlox-TKI
EGFR
     
CL-387785
EGFR, IC50: 370 pM
      98.10%
AV-412
EGFR, IC50: 0.75 nM
EGFRL858R, IC50: 0.5 nM
EGFRT790M, IC50: 0.79 nM
EGFRL858R/T790M, IC50: 2.3 nM
ErbB2, IC50: 19 nM
    99.17%
Mutated EGFR-IN-1
EGFRL858R
EGFRExon 19 deletion/T790M
EGFRT790M
      99.89%
Epertinib hydrochloride
EGFR, IC50: 1.48 ± 0.0 nM
HER2, IC50: 7.15 nM
 
HER4, IC50: 2.49 ± 0.1 nM
98.25%
MTX-211
EGFR
      ≥98.0%
Astragaloside VI
EGFR
      99.95%
AG-825
EGFR, IC50: 19 μM
ErbB2, IC50: 0.35 μM
    98.07%
Naquotinib mesylate
EGFRL858R/T790M
EGFRL858R
EGFRExon 19 deletion
EGFRExon 19 deletion/T790M
EGFR, IC50: 230 nM
      98.02%
DBPR112
EGFRL858R/T790M, IC50: 48 nM
EGFRWT, IC50: 15 nM
      98.07%
EGFR-IN-12
EGFR (WT), IC50: 21 nM
EGFRL858R, IC50: 63 nM
EGFRL861Q, IC50: 4 nM
   
HER4, IC50: 7640 nM
99.49%
RG14620
EGFR, IC50: 3 μM (Cell Assay)
      98.09%
CNX-2006
EGFRT790M, IC50: 20 nM
      99.68%
AV-412 free base
EGFR, IC50: 0.75 nM
EGFRL858R, IC50: 0.51 nM
EGFRL858R/T790M, IC50: 2.3 nM
EGFRT790M, IC50: 0.79 nM
ErbB2, IC50: 19 nM
    98.33%
Almonertinib hydrochloride
EGFRT790M, IC50: 0.37 nM
EGFRL858R/T790M, IC50: 0.29 mM
EGFRdel19 T790M, IC50: 0.214 nM
      98.03%
Rezivertinib
EGFR
      99.93%
Tyrphostin AG 528
EGFR, IC50: 4.9 μM
ErbB2, IC50: 2.1 μM
    ≥98.0%
PD-161570
EGFR, IC50: 240 nM
      99.04%
Simotinib
EGFR, IC50: 19.9 nM
      99.70%
PD153035 Hydrochloride
EGFR, Ki: 6 pM
EGFR, IC50: 25 pM
      99.06%
limertinib
EGFRT790M, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 0.3 nM
EGFR (WT), IC50: 6 nM
EGFRExon 19 deletion, IC50: 0.5 nM
      98.01%
Pertuzumab (PBS)  
HER2
    98.32%
EGFR/ErbB-2/ErbB-4 inhibitor-2
EGFR, IC50: 0.017 μM
ErbB2, IC50: 0.08 μM
 
ErbB4, IC50: 1.91 μM
99.69%
Rociletinib hydrobromide
EGFRL858R/T790M, Ki: 21.5 nM
EGFRT790M, Ki: 303.3 nM
      98.04%
HG-14-10-04
EGFRLR/TM, IC50: 15.6 nM
EGFR19del/TM/CS, IC50: 22.6 nM
EGFRLR/TM/CS, IC50: 124.5 nM
      98.83%
EGFR-IN-1 TFA
EGFRL858R/T790M
      99.05%
Theliatinib
EGFR, IC50: 3 nM
EGFR, Ki: 0.05 nM
EGFR (L858R/T790M), IC50: 22 nM
      99.88%
(S)-Sunvozertinib
EGFR exon 20 NPH, IC50: 51.2 nM
EGFR exon 20 ASV insertion, IC50: 51.9 nM
EGFRL858R/T790M, IC50: 1 nM
Her2 exon 20 YVMA insertion, IC50: 21.2 nM
    99.14%
AG-494
EGFR, IC50: 0.7 μM
      99.06%
EGFR-IN-69
EGFR L858R/T790M/C797S, IC50: 4.3 ± 0.9 nM
EGFRL858R/T790M, IC50: 6.6 ± 0.8 nM
EGFRdel19 T790M C797S, IC50: 25.6 ± 7.5 nM
EGFRWT, IC50: 816.0 ± 82 nM
      99.55%
NRC-2694
EGFR
      99.45%
Naquotinib
EGFR, IC50: 230 nM
     
Lapatinib ditosylate monohydrate
EGFR, IC50: 10.8 nM
ErbB2, IC50: 9.2 nM
    99.78%
Epertinib
EGFR, IC50: 1.48 ± 0.0 nM
HER2, IC50: 7.15 ± 0.5 nM
 
HER4, IC50: 2.49 ± 0.1 nM
≥98.0%
EGFR-IN-11
EGFRL858R/T790M/C797S, IC50: 18 nM
      99.81%
JBJ-09-063
EGFR L858R, IC50: 0.147 nM
EGFR L858R/T790M, IC50: 0.063 nM
EGFR L858R/T790M/C797S, IC50: 0.083 nM
EGFRLT/L747S, IC50: 0.396 nM
     
Mutated EGFR-IN-3
EGFRL858R/T790M, IC50: 12 nM
EGFRC797S, IC50: 13 nM
     
BI-1622  
HER2, IC50: 7 nM
    98.97%
(E)-AG 99
EGFR
      98.36%
BI-4142  
HER2, IC50: 5 nM
    98.09%
JBJ-04-125-02
EGFR (L858R/T790M), IC50: 0.26 nM
     
EGFR-IN-1
EGFRL858R/T790M
     
JBJ-09-063 hydrochloride
EGFR L858R, IC50: 0.147 nM
EGFR L858R/T790M, IC50: 0.063 nM
EGFR L858R/T790M/C797S, IC50: 0.083 nM
EGFRLT/L747S, IC50: 0.396 nM
     
AG 555
EGFR
      ≥98.0%
Mutant EGFR inhibitor
EGFRL858R
EGFRExon 19 deletion
EGFRT790M
      99.51%
Nazartinib mesylate
EGFRL858R/T790M, Ki: 31 nM
     
ZD-4190
EGFR
      99.20%
BGB-102
EGFR, IC50: 9.6 nM
HER2, IC50: 18 nM
 
HER4, IC50: 40.3 nM
Alflutinib
EGFR
     
Afatinib oxalate
EGFRL858R, IC50: 0.4 nM
EGFRWT, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 10 nM
HER2, IC50: 14 nM
   
JBJ-02-112-05
EGFRL858R/T790M, IC50: 15 nM
     
Mobocertinib mesylate
EGFR exon 20 insertion
EGFR (WT)
HER2
   
Lapatinib tosylate
EGFR, IC50: 10.2 nM
ErbB2, IC50: 9.8 nM
   
MC-Val-Cit-PAB-Amide-TLR7 agonist 4  
HER2
    99.39%
EGFR/CSC-IN-1
EGFR, IC50: 10.52 nM
     
EMI48
EGFRL858R/T790M/C797S
EGFRdel19 T790M C797S
      99.02%
MS9427
EGFR (WT), Kd: 7.1 nM
EGFR L858R, Kd: 4.3 nM
     
MS9449
EGFR (WT), Kd: 17 nM
EGFR L858R, Kd: 10 nM
     
Mutated EGFR-IN-2
EGFR (L858R/T790M), IC50: <1 nM
     
Oritinib mesylate
EGFR (WT), IC50: 18 nM
EGFRL858R, IC50: 0.7 nM
EGFRL861Q, IC50: 4 nM
EGFRL858R/T790M, IC50: 0.1 nM
EGFRd746-750, IC50: 1.4 nM
EGFRd746-750/T790M, IC50: 0.89 nM
     
EGFR-IN-15
EGFR, IC50: 4 nM
     
Oritinib
EGFR (WT), IC50: 18 nM
EGFRL858R, IC50: 0.7 nM
EGFRL861Q, IC50: 4 nM
EGFRL858R/T790M, IC50: 0.1 nM
EGFRd746-750, IC50: 1.4 nM
EGFRd746-750/T790M, IC50: 0.89 nM
      99.18%
EGFR/HER2-IN-2
EGFR, IC50: 5.02 μM
HER2, IC50: 0.83 μM
   
EGFR-IN-1 hydrochloride
EGFRL858R/T790M
     
Sacibertinib
EGFR-TK phosphorylation, EC50: 110 nM
HER2, EC50: 244 nM
   
EMI56
EGFRL858R/T790M/C797S
EGFRdel19 T790M C797S
      99.72%
EGFR-IN-17
EGFR (C797S/T790M/L858R), IC50: 0.0002 μM
      98.42%
Neratinib maleate
EGFR, IC50: 92 nM
HER2, IC50: 59 nM
   
SU 5402 (GMP)
EGFR, IC50: 30 nM
     
CHMFL-EGFR-202
EGFRT790M, IC50: 5.3 nM
EGFR, IC50: 8.3 nM
ErbB2, IC50: 8.1 nM
 
ErbB4, IC50: 3.2 nM
EGFR-IN-5
EGFR, IC50: 10.4 nM
EGFRL858R, IC50: 1.1 nM
EGFRL858R/T790M, IC50: 34 nM
EGFRL858R/T790M/C797S, IC50: 7.2 nM
     
HER2-IN-5  
HER2
   
EGFR-IN-36
EGFR (WT), IC50: 19.09 nM
HER2(WT), IC50: 120.01 nM
HER2 (A775_G776insYVMA), IC50: 2.35 nM
   
EGFR/BRAF-IN-1
EGFR
     
pan-HER-IN-1
EGFR, IC50: 0.38 nM
EGFRL858R/T790M/C797S, IC50: 2.2 nM
HER2, IC50: 3.5 nM
 
HER4, IC50: 1.6 nM
EGFR/HER2-IN-5
EGFR, IC50: 0.6 nM
HER2, IC50: 0.6 nM
   
HER2-IN-12  
HER2, IC50: 121 nM
   
SU5204  
HER2, IC50: 51.5 μM
    98.89%
Lavendustin C
EGFR, IC50: 0.012 μM
     
PROTAC EGFR degrader 5
EGFR, DC50: 34.8 nM
     
HKI-357
EGFR, IC50: 34 nM
ErbB2, IC50: 33 nM
    99.65%
HER2-IN-8  
HER2
   
EGFR-IN-46
EGFR, IC50: 20.17 nM
     
(E/Z)-CP-724714  
HER2
   
PDE5-IN-3
EGFR, IC50: 5.827 μM
     
EGFR-IN-60
EGFR, IC50: 0.083 μM
EGFRL858R, IC50: 0.053 μM
EGFRT790M, IC50: 0.026 μM
     
EGFR-IN-62
EGFRL858R/T790M, IC50: 10 ± 1
EGFR (WT), IC50: 29 ± 2
EGFRL858R/T790M/C797S, IC50: 242 ± 9
     
EGFR-IN-52
EGFR, IC50: 0.358 μM
EGFRL858R, IC50: 86.02 μM
EGFRT790M, IC50: 432.67 μM
     
EGFR-IN-3
EGFRWT, IC50: 0.32 μM
     
EGFR-IN-49
EGFRT790M, IC50: 65.0 nM
EGFRL858R/T790M, IC50: 13.6 nM
     
EGFR-IN-73
EGFRdel19, IC50: 119 nM
EGFRL858R, IC50: 820 nM
EGFRWT, IC50: >10 μM
EGFRL858R/T790M, IC50: >10 μM
     
Selatinib
EGFR, IC50: 13 nM
ErbB2, IC50: 22.5 nM
   
PD-089828
EGFR, IC50: 5.47 μM
EGFR, Ki: 3.16 μM
     
EGFR-IN-21
EGFR, IC50: 0.38 nM
     
EGFR-IN-28
EGFR
     
EGFR/ErbB-2/ErbB-4 inhibitor-3
ErbB1, IC50: 0.3 nM
EGFR, IC50: 2.5 nM
ErbB2, IC50: 1.1 nM
 
ErbB4, IC50: 0.5 nM
EGFR/HER2/TS-IN-2
EGFR, IC50: 0.173 ± 0. μM
HER2, IC50: 0.125 ± 0. μM
   
EGFR/HER2-IN-4
EGFR, IC50: 0.6 nM
     
EGFR-IN-55
EGFRL858R/T790M, IC50: 3.9 nM
EGFRWT, IC50: 70 nM
     
PROTAC EGFR degrader 2
EGFR, DC50: 36.51 nM
     
EGFR/HER2-IN-3
EGFR
HER2
   
EGFR-IN-29
EGFRT790M
     
pan-HER-IN-2
EGFR, IC50: 0.72 nM
EGFR (L858R/T790M), IC50: 8.2 nM
HER2, IC50: 75.1 nM
 
HER4, IC50: 2.0 nM
EGFR-IN-22
EGFRL858R/T790M/C797S, IC50: 0.54 nM
EGFR (WT), IC50: 4.91 nM
     
RET-IN-19
EGFR, IC50: 56.78 ± 4. μM
     
DPPY
EGFR, IC50: <10 nM
     
HSP90-IN-13
EGFR, IC50: 38.5 nM
     
HER2-IN-9  
HER2, IC50: 0.03 μM
   
EGFR kinase inhibitor 1
EGFR (WT), IC50: 37 nM
EGFRL858R/T790M, IC50: 1.7 nM
EGFRL858R/T790M/C797S, IC50: >300 nM
     
EGFR-IN-56
EGFRT790M, IC50: 541.7 nM
EGFRL858R/T790M, IC50: 132.1 nM
     
EGFR-IN-27
EGFRdel19, IC50: <50 nM
EGFRL858R, IC50: <50 nM
EGFRL858R/T790M, IC50: <50 nM
EGFRdel19 T790M C797S, IC50: <50 nM
EGFR (C797S/T790M/L858R), IC50: <50 nM
EGFRdel19 T790M, IC50: <50 nM
     
EGFR-IN-30
EGFR (WT), IC50: 1-10 nM
EGFR (L858R/T790M/C797S), IC50: <1 nM
     
Simotinib hydrochloride
EGFR, pIC50: 19.9 nM
     
EGFR-IN-57
EGFR, IC50: 0.054 μM
     
EGFR-IN-16
EGFR, pIC50: 4.85
HER2, pIC50: 4.74
   
EGFR-IN-67
EGFR, IC50: 0.34 μM
     
JNJ28871063 hydrochloride
ErbB1, IC50: 22 nM
ErbB2, IC50: 38 nM
 
ErbB4, IC50: 21 nM
EGFR-IN-64
EGFR, IC50: 0.33 μM
     
EGFR-IN-54
EGFR, IC50: 1.623 μM
     
EGFR-IN-9
EGFR (WT), IC50: 7 nM
EGFRL858R/T790M, IC50: 28 nM
      98.84%
EMI1
EGFRdel19 T790M C797S
EGFRL858R/T790M/C797S
     
EGFR/HER2/TS-IN-1
EGFR, IC50: 0.203 μM
HER2, IC50: 0.088 μM
   
VEGFR-IN-1
EGFR, IC50: 0.24 μM
     
Tyrphostin 8
EGFR, IC50: 560 μM
     
EGFR-IN-45
EGFR, IC50: 0.4 μM
     
EGFR-IN-40
EGFR, IC50: 5.3 nM
     
EGFR-IN-53
EGFR, IC50: 8.264 μM
     
EGFR-IN-51
EGFR, IC50: 0.493 μM
EGFRL858R, IC50: 102.60 μM
EGFRT790M, IC50: 461.63 μM
     
EGFR-IN-61
EGFRL858R/T790M, IC50: 42 ± 2 nM
EGFRL858R/T790M/C797S, IC50: 137 ± 6 nM
EGFR (WT), IC50: 743 ± 20 nM
     
AG-1478 hydrochloride
EGFR, IC50: 3 nM
     
CGP52411
EGFR, IC50: 0.3 μM
      99.82%
PF-6274484
EGFR (WT), Ki: 0.18 nM
EGFRL858R/T790M, Ki: 0.14 nM
      98.41%
PROTAC EGFR degrader 7
EGFRL858R/T790M, DC50: 13.2 nM
     
Nelipepimut-S  
HER2
   
WHI-P180 hydrochloride
EGFR, IC50: 4 μM
     
Erlotinib mesylate
EGFR, IC50: 2 nM
     
Allitinib
EGFR, IC50: 0.5 nM
EGFRL858R/T790M, IC50: 12 nM
ErbB2, IC50: 3 nM
 
ErbB4, IC50: 0.8 nM